Chemotherapy for advanced-stage non-small cell lung cancer

Lingling Du, Daniel Morgensztern

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Use of platinum-based chemotherapy doublets is the standard of care for patients with advanced-stage non-small cell lung cancer, being associated with improved survival compared with best supportive care in fit patients with good performance status. Randomized studies showed that the addition of monoclonal antibodies against vascular endothelial growth factor receptor or epidermal growth factor receptor may increase the survival compared to chemotherapy alone. Patients with either advanced age or poor performance status can also benefit from chemotherapy. Docetaxel with or without ramucirumab, pemetrexed, and erlotinib are approved for previously treated patients. New treatment approaches are needed to improve the outcomes in this patient population.

Original languageEnglish
Pages (from-to)366-370
Number of pages5
JournalCancer Journal (United States)
Issue number5
StatePublished - Sep 1 2015


  • Epidermal growth factor receptor
  • Monoclonal antibodies
  • Non-small cell lung cancer
  • Survival
  • Vascular endothelial growth factor receptor


Dive into the research topics of 'Chemotherapy for advanced-stage non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this